Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

The world’s first “digital data-fingerprint” for human blood samples.

Project description

Digital solution for ensuring human blood sample quality

Most medical decisions today depend on diagnostics results. However, blood samples are sensitive to environmental conditions, with handling, transport and storage affecting their quality. Poor quality of human blood samples that doesn't meet the criteria of laboratory analysers can lead to erroneous test results and unnecessary medical treatments. Given the importance of the quality of human blood samples for downstream analysis, the EU-funded S4DX project is working on an innovative technology that digitally monitors the quality of human samples in real time until they arrive at the lab for analysis. The data collected through transport and handling accumulate, providing a human sample fingerprint that will serve as the baseline for highly sensitive tests.

Objective

"Smart4Diagnostics (S4DX) has developed the world’s first “digital human sample data-fingerprint” for human blood samples in pre-preanalytics. We aks for EIC-support to catapult this innovation into a market-changing product.

S4DX detects and reduces pre-preanalytical errors at sample collection when patients are still present. This is a quantum leap in quality and safety for patients, doctors and laboratories. They receive reliable results and painful re-visits and re-collection of samples are avoided. With our innovation we change medical diagnostics from ""trust-based” to “evidence-based”. We provide a complete dataset on the quality of each human sample from blood draw until analysis. Our solution provides the new pre-preanalytical data-standard for sensitive medical diagnostics in the future. S4DX “digital human sample fingerprint” will be the necessary data-baseline for highly sensitive tests (e.g. liquid biopsy). Market-entry in Europe with our MVP is planned for Dec. 2020. Our data will be used to refine our pattern-recognition algorithms and thus provide the basis for personalized and precision diagnostics.

We collaborate with leading international partners. Roche Diagnostics and Sarstedt are technical advisors, leading European lab chains (Bioscientia/Germany, Medisupport/Switzerland and Certe/ Netherlands) are implementation partners; Würth Electronics provides access to manufacturers and supply chain partners.

The company was founded in Jan. 2018, won the EIT-Health Wildcard as best eHealth start-up in Europe, the Hackathon of the TU Munich/Germany as best start-up and was chosen globally by the WHO as one of ten most promising start-ups in 2018. In April 2019 the Investment committee of the High-Tech-Gründerfonds voted unanimously to accept S4DX for further investment of 1 Mio. €, in July 2019 ACI/ Boston accepted us as one of six companies globally in the “Gold-Track-Program” for massive global scaling in healthcare.
"

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

SME-2 - SME instrument phase 2

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

SMART4DIAGNOSTICS GMBH
Net EU contribution
€ 1 034 075,00
Address
RUPERT MAYER STRASSE 44
81379 Munich
Germany
SME
Yes
Region
Bayern Oberbayern München, Kreisfreie Stadt
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 1 477 250,00